UK NEQAS LI has recently assessed the implementation of the National Institute for Health and Care Excellence (NICE) haematological cancers improving outcomes guidelines (NG47) across Specialist Integrated Haematological Malignancy Diagnostic Services in England. Read about the findings here:

https://jcp.bmj.com/content/early/2022/05/03/jclinpath-2021-208075

Supporting Your Point of Care Testing (POCT) Service is a full-day, face-to-face event, taking place at the Hyatt Regency Hotel in Birmingham on 30th June 2022.

Delegates who attend the event will hear from a variety of speakers who have experience in either accrediting, developing, delivering, or supporting a Point of Care Testing (POCT)/Near Patient Testing service.

This event will benefit staff from many sectors, including, but not limited to, staff working within a retail/community pharmacy setting, GPs, Practice Nurses, and staff working within a laboratory who are already offering, or considering offering POC testing.

To book your place please follow this link: https://ukneqas.org.uk/events/supporting-your-point-of-care-testing-service/

UK NEQAS LI was recently part of an international harmonized study for data analysis in the evaluation of multiple myeloma residual disease by high sensitivity flow cytometry. Read about the findings here:

https://onlinelibrary.wiley.com/doi/full/10.1002/cyto.b.22053

UK NEQAS LI’s new Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods is now available for registration for the April 2022- March 2023 registration period. http://www.ukneqasli.org/sampleentry/

Please find information about the programme here: http://www.ukneqasli.co.uk/eqa-pt-programmes/molecular-haemato-oncology-programmes/new-measurable-residual-disease-for-aml-by-molecular-methods-pilot-not-accredited/

However, following a number of requests from participants we are planning to issue a round in the next few weeks to familiarise participants with the programme before the 2022/2023 participation period. This will be separate to the standard reregistration process. Please note by registering for this optional extra round you will not automatically be included in the programme for the 2022-2023 period, you will need to complete the online re-registration process via the participant hub. If you’re interested in being included in the optional extra round in March 2022 please contact admin@ukneqasli.co.uk to register or provide a quote.

Read the latest publication from UK NEQAS LI that has assessed the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in AML:

https://onlinelibrary.wiley.com/doi/10.1111/bjh.18023

As part of the continuous development of our EQA/PT provision we will be introducing a number of updates to our flow cytometry and molecular haematology programmes in 2022-2023.

The re-registration period for the 2022-2023 year opens on the 1st February 2022.

Please see the molecular and flow cytometry pages on the website for further details. 

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS accredited proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.

You can find our schedule of accreditation here.

Also a link to the UKAS website can be found here, where you will be able to view and download a PDF of our current accreditation certificate.

UK NEQAS for Leucocyte Immunophenotyping (UK NEQAS LI) now has a Facebook page and a Twitter account. We will be posting important messages to these accounts relating to our schemes so please like or follow us, respectively.

We hope that these feeds will act as a useful eductational resource for participants and collaborators alike, collating interesting papers, conference info, videos and news stories in haemato-oncology. As we develop our online presence we hope to publish some of our own educational content. If you have any feedback or ideas as to content you would like us to include, please do not hesitate to get in touch.